Medical Devices APAC

APAC Insulin Delivery Devices Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Insulin Delivery Devices Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Product Type, By Distribution Channel, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $3.60 Bn Placeholder estimate
Estimate 2025 $3.88 Bn 21.5% of the global market
Projected 2034 $7.60 Bn 96.1% Adds $3.72 Bn over 9 forecast years
CAGR 2025–2034 7.77% Faster than 22% of 173 Medical Devices markets here
Key players 6 +1
  • APAC is 21.5% of the global market.
  • Among regions, the largest is North America at $8.84 Bn.
  • Fastest growing: Africa at 8% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.72 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Insulin Delivery Devices Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $3.60 Bn — —
2025 (base) $3.88 Bn +$279.4 Mn —
2026 (forecast) $4.18 Bn +$301.1 Mn +7.8%
2027 (forecast) $4.50 Bn +$324.5 Mn +16.1%
2028 (forecast) $4.85 Bn +$349.7 Mn +25.2%
2029 (forecast) $5.23 Bn +$376.9 Mn +34.9%
2030 (forecast) $5.63 Bn +$406.2 Mn +45.4%
2031 (forecast) $6.07 Bn +$437.8 Mn +56.7%
2032 (forecast) $6.54 Bn +$471.8 Mn +68.8%
2033 (forecast) $7.05 Bn +$508.4 Mn +82%
2034 (forecast) $7.60 Bn +$548.0 Mn +96.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Insulin Delivery Devices Market Analysis at a glance
Market size, 2025$3.88 Bn placeholder estimate
Forecast, 2034$7.60 Bn placeholder estimate
Growth (CAGR), 2025–20347.77% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct type and distribution channel (see all)
Key playersNovo Nordisk A/S, Medtronic, Sanofi, Abbott Laboratories, Eli Lilly and Company and 1 more (see all)
Active clinical trials44 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Insulin Delivery Devices Market Executive Summary

Diabetes is a disease that requires careful administration of Insulin through Insulin delivery devices to maintain blood sugar levels. These are insulin pens (reusable and disposable), that can administer a continuous supply of insulin through a catheter known as insulin pump, syringe injections, and jet injectors which are needleless. Other creative possibilities are inhalers and patches. These devices assist patients to regulate blood glucose levels, convenience and advance diabetes self-management with facilities such as programmable dosage and tracking. The IDF Diabetes Atlas (2021) reports that 10.5% of the adult population (20-79 years) has diabetes, with almost half unaware that they are living with the condition.

The global market for insulin delivery devices is expanding at a fairly constant rate due to increasing rates of diabetes, innovative technologies, and high consumer demand for improved insulin administration essentials. Leading vendors include Medtronic, Novo Nordisk, and Eli Lilly, while regions such as North America and Asia-Pacific exhibit the highest level of technology maturity. Some of the challenges include high costs, stringent regulations, and competition from other diabetes oral tablets. Future trends in innovation include the use of artificial intelligence, wearable technology, and biosimilar medication that is cheaper and accessible to the population.

Bar chart: Asia Pacific Insulin Delivery Devices market size, 2024–2034, placeholder estimates. $3.60 Bn in 2024, $3.88 Bn in 2025 and $7.60 Bn in 2034, 7.77% CAGR.
Asia Pacific Insulin Delivery Devices market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Insulin Delivery Devices Market Dynamics

Market Growth Drivers

The increasing incidence of diabetes, influenced by urban development, an aging demographic, and shifts in lifestyle, serves as a significant catalyst, with a growing population of elderly and overweight individuals necessitating insulin therapy. Technological innovations, including intelligent insulin delivery systems and continuous glucose monitoring tools, significantly improve diabetes management, while advantageous reimbursement frameworks and escalating healthcare investments in developing regions further bolster market expansion.

Opportunity

Innovations in artificial pancreas systems (APS) are poised to enhance precision and ease of use, thereby improving glycemic control. Cutting-edge delivery modalities such as transdermal patches and inhalable insulin are anticipated to offer non-invasive and less frequent administration alternatives. The incorporation of digital health technologies, encompassing mobile applications and data analytics, will facilitate a more customized and proactive approach to diabetes management. Furthermore, the expansion of healthcare infrastructure and increased awareness in emerging markets, particularly in Asia and Africa, create opportunities for affordable insulin solutions.

Market Restraints

The elevated expenses associated with advanced medical devices, such as insulin pumps and smart pens, hinder their adoption, particularly in developing nations with constrained healthcare budgets. Product recalls and safety apprehensions, including cybersecurity vulnerabilities related to connected devices, can undermine consumer confidence and impede market growth. Practical challenges, such as the size and discomfort of certain devices, further restrict patient acceptance. Moreover, rigorous regulatory standards may postpone the launch of innovative products, thereby decelerating market expansion.

Competitive Landscape for Insulin Delivery Devices Market in APAC

Key Players

Recent Developments

August 2024, FDA Clears First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes. Agency Supports Broader Access to Innovative Technology in Diabetes Management.

February 2024, Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.

June 2024, Insulet Corporation has announced that its Omnipod 5, a tubeless automated insulin delivery system compatible with Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitors, is fully available in the U.K. and the Netherlands. This marks the first AID system integrated with both leading CGM brands and is approved for use by individuals aged two years and older with type 1 diabetes.

June 2024, CeQur Simplicity™, a Wearable Mealtime Insulin Delivery Device, Obtains FDA-Clearance for 4 Days of Wear to Further Simplify Diabetes Management.

May 2025, FDA Cleared New Insulin Pump and Algorithm-Based Software to Support Enhanced Automatic Insulin Delivery. Agency Continues to Support Innovation of Next-Generation Technology in Diabetes Management.

Mergers and Acquisitions

February 2024, Catalent was recently acquired by Novo Holdings for $16.5 billion. This deal was slated to close later in 2024. As part of the deal, Novo Nordisk has agreed to acquire three fill-finish sites from Novo Holdings for $11 billion—the sites are in Italy, Belgium, and Bloomington, IN, in the U.S.

May 2025, Medtronic plc announced its acquisition of EOFlow Co. Ltd., the manufacturer of the EOPatch®, a tubeless, wearable, and fully disposable insulin delivery device. This acquisition, combined with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor (CGM), is expected to enhance Medtronic's ability to meet the diverse needs of individuals with diabetes, regardless of their treatment preferences or stage in their diabetes management journey.

Healthcare Policies and Regulatory Landscape for Insulin Delivery Devices Market in APAC

Insulin Delivery Devices in APAC: rules, payment and research

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 44 studies on Insulin Delivery Devices that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 9 Nov 2026.

Policy changes and Reimbursement scenario

Numerous nations, especially in North America, possess comprehensive reimbursement policies that facilitate patient access to advanced diabetes management solutions. Nonetheless, coverage may vary, with developed markets typically providing extensive support while developing regions encounter challenges. Emerging markets such as India and China are anticipated to experience advancements in reimbursement as their healthcare systems evolve. Furthermore, policy modifications are influencing the market, with an increasing emphasis on preventive care, enhanced support for telehealth, and expedited regulatory approval processes improving access to and adoption of novel technologies.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Insulin Delivery Devices right now, from free public sources.

Clinical trials

44 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Novo Nordisk A/S 7 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Insulet Corporation 6 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Medtronic 4 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Sanofi 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Amgen Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Diabetes (adults), % of adults (WHO)
CountryValueYear
Afghanistan25.32022
Australia8.12022
Bangladesh17.92022
China11.22022
India22.62022
Indonesia12.82022
Japan6.42022
Malaysia26.72022
Myanmar13.82022
Nepal15.82022
New Zealand9.02022
Pakistan30.92022
Philippines13.22022
Singapore13.12022
Thailand12.32022
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Insulin Delivery Devices in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Insulin Delivery Devices market in Asia Pacific?
Placeholder estimate: about $3.88 Bn in 2025, rising to about $7.60 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Insulin Delivery Devices market in Asia Pacific growing?
Placeholder estimate: about 7.77% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Insulin Delivery Devices market report cover?
The report splits the market by product type (Insulin Pens, Insulin Syringes, Insulin Pumps, Jet Injectors and more) and distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Diabetes Clinics/Centers).
Who are the key players in the Insulin Delivery Devices market?
Key players include Novo Nordisk A/S, Medtronic, Sanofi, Abbott Laboratories, Eli Lilly and Company and Wockhardt Ltd..
What is driving the Insulin Delivery Devices market?
The increasing incidence of diabetes, influenced by urban development, an aging demographic, and shifts in lifestyle, serves as a significant catalyst, with a growing population of elderly and overweight individuals necessitating insulin therapy.
How many clinical trials on Insulin Delivery Devices are running in Asia Pacific?
44 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 9 Nov 2026.
How much research is published on Insulin Delivery Devices?
PubMed lists 3,597 papers on Insulin Delivery Devices added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on diabetes

See the topic